Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype

Journal of Oncology
M V GiuliS Checquolo

Abstract

Triple-negative breast cancer (TNBC) is a subgroup of 15%-20% of diagnosed breast cancer patients. It is generally considered to be the most difficult breast cancer subtype to deal with, due to the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which usually direct targeted therapies. In this scenario, the current treatments of TNBC-affected patients rely on tumor excision and conventional chemotherapy. As a result, the prognosis is overall poor. Thus, the identification and characterization of targets for novel therapies are urgently required. The Notch signaling pathway has emerged to act in the pathogenesis and tumor progression of TNBCs. Firstly, Notch receptors are associated with the regulation of tumor-initiating cells (TICs) behavior, as well as with the aetiology of TNBCs. Secondly, there is a strong evidence that Notch pathway is a relevant player in mammary cancer stem cells maintenance and expansion. Finally, Notch receptors expression and activation strongly correlate with the aggressive clinicopathological and biological phenotypes of breast cancer (e.g., invasiveness and chemoresistance), which are relevant characteristics of TNBC subtype. The purp...Continue Reading

References

Nov 1, 1996·Journal of Virology·J L RohnJ Overbaugh
Apr 30, 1999·Science·S Artavanis-TsakonasR J Lake
Nov 11, 1999·Oncogene·A DiévartP Jolicoeur
Jul 28, 2004·The American Journal of Pathology·Hippokratis KiarisSpyros Artavanis-Tsakonas
Sep 24, 2004·Advances in Experimental Medicine and Biology·Russell C Hovey, Josephine F Trott
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikita A MakretsovC Blake Gilks
Oct 20, 2004·The Journal of Cell Biology·Salvatore PecePier Paolo Di Fiore
Nov 3, 2004·Cancer Research·Xing FanCharles G Eberhart
Jul 19, 2005·Journal of Mammary Gland Biology and Neoplasia·Wende Kozlow, Theresa A Guise
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Aug 22, 2006·Nature Reviews. Molecular Cell Biology·Sarah J Bray
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marija BalicRichard J Cote
May 18, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Brendan C DicksonMichael Reedijk
Aug 1, 2007·BMC Genomics·Katherine A HoadleyCharles M Perou
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Aug 7, 2007·The American Journal of Pathology·Christine F O'NeillLucy Liaw
Sep 14, 2007·Nature Reviews. Cancer·John Stingl, Carlos Caldas
Sep 18, 2007·Stem Cell Reviews·Gillian Farnie, Robert B Clarke
Oct 3, 2007·Cancer Research·Shahab AkhoondiCharles Spruck
Nov 21, 2007·Breast Cancer Research and Treatment·Joyce O'Shaughnessy
Oct 9, 2007·Trends in Biochemical Sciences·Jing Wu, Emery H Bresnick
Nov 9, 2007·Breast Cancer Research and Treatment·Michael ReedijkIrene L Andrulis
Sep 2, 2008·Oncogene·D BellaviaI Screpanti
Sep 2, 2008·Oncogene·B D'SouzaG Weinmaster
Nov 26, 2008·Breast Cancer Research : BCR·Connie W LeeDario C Altieri
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabrice AndreLajos Pusztai
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A U Buzdar
Jan 20, 2009·Nature Cell Biology·Alessandra RustighiGiannino Del Sal
Feb 10, 2009·Journal of the National Comprehensive Cancer Network : JNCCN·Robert W CarlsonUNKNOWN NCCN Breast Cancer Clinical Practice Guidelines Panel
Apr 22, 2009·Cell·Raphael Kopan, Maria Xenia G Ilagan
Jun 25, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B K LinderholmR Lewensohn
Aug 12, 2009·Cell Stem Cell·Timothy HoeyAustin Gurney

❮ Previous
Next ❯

Citations

Mar 27, 2020·Medical Sciences : Open Access Journal·Ugo TestaElvira Pelosi
Apr 17, 2020·Frontiers in Cell and Developmental Biology·Wenchen PuYong Peng
Oct 7, 2020·Molecular Biology Reports·Meng-Cheng LiuJamie J Newman
Dec 10, 2020·Nature Reviews. Drug Discovery·Samarpan MajumderLucio Miele
May 7, 2020·Current Cancer Drug Targets·Mamta KumariPiyong Sola
Nov 4, 2020·Neoplasia : an International Journal for Oncology Research·Sebastien Taurin, Haifa Alkhalifa
Jan 12, 2021·Frontiers in Cell and Developmental Biology·Sabrina ZemaDiana Bellavia
Apr 28, 2020·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Rama Rao MallaVenkata Ramesh Dasari
Mar 16, 2021·Frontiers in Oncology·Yingshu CaoKe Wang
Jun 23, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Anqi LinJian Zhang
May 18, 2021·Chemistry & Biodiversity·Han ChenXiaoling Lu
Nov 1, 2020·Life Sciences·Cheryl Qian Ying Yong, Bor Luen Tang
Jul 3, 2021·Biomolecules·Han Leng NgDaniela Ulgiati
Aug 13, 2021·Frontiers in Molecular Biosciences·Dong ZhangQifeng Yang
Aug 15, 2021·Proceedings of the National Academy of Sciences of the United States of America·Wanfu WuJan-Ake Gustafsson

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.